Bonnie L. Bermas, Irene Blanco, Ashira D. Blazer, Megan EB Clowse, Cuoghi Edens, Rosalind Ramsey-Goldman, Mehret Birru Talabi
doi : 10.1002/art.42336
Leonard H. Calabrese, Cassandra M. Calabrese, Elizabeth Kirchner, Kevin Winthrop
doi : 10.1002/art.42334
Peter C. Grayson, Cristina Ponte, Ravi Suppiah, Joanna C. Robson, Katherine Bates Gribbons, Andrew Judge, Anthea Craven, Sara Khalid, Andrew Hutchings, Debashish Danda, Raashid A. Luqmani, Richard A. Watts, Peter A. Merkel, for the DCVAS Study Group
doi : 10.1002/art.42324
To develop and validate new classification criteria for Takayasu arteritis (TAK).
Cristina Ponte, Peter C. Grayson, Joanna C. Robson, Ravi Suppiah, Katherine Bates Gribbons, Andrew Judge, Anthea Craven, Sara Khalid, Andrew Hutchings, Richard A. Watts, Peter A. Merkel, Raashid A. Luqmani, for the DCVAS Study Group
doi : 10.1002/art.42325
To develop and validate updated classification criteria for giant cell arteritis (GCA).
Yiqiang Zhan, Xiaoying Kang
doi : 10.1002/art.42313
Christopher McMaster, Alix Bird, David F. L. Liew, Russell R. Buchanan, Claire E. Owen, Wendy W. Chapman, Douglas E. V. Pires
doi : 10.1002/art.42296
Deep learning has emerged as the leading method in machine learning, spawning a rapidly growing field of academic research and commercial applications across medicine. Deep learning could have particular relevance to rheumatology if correctly utilized.
Patients with immune-mediated inflammatory diseases (IMIDs) receiving B cell–depleting therapy (BCDT) are among the most vulnerable to severe COVID-19, as well as the most likely to suboptimally respond to SARS–CoV-2 vaccines. However, little is known about the frequency or severity of breakthrough infection in this population. We retrospectively analyzed a large group of vaccinated IMID patients undergoing BCDT in order to identify breakthrough COVID-19 infections and assess their outcomes.
doi : 10.1002/art.42287
Jing Wang, Donna Conlon, Felice Rivellese, Alessandra Nerviani, Myles J. Lewis, William Housley, Marc C. Levesque, Xiaohong Cao, Carolyn Cuff, Andrew Long, Costantino Pitzalis, Melanie C. Ruzek
doi : 10.1002/art.42295
This study was undertaken to understand the mechanistic basis of response to anti–tumor necrosis factor (anti-TNF) therapies and to determine whether transcriptomic changes in the synovium are reflected in peripheral protein markers.
Can M. Sungur, Jonathan C. Baker
doi : 10.1002/art.42312
Ghazaleh Tavallaee, Starlee Lively, Jason S. Rockel, Shabana Amanda Ali, Michelle Im, Clementine Sarda, Greniqueca M. Mitchell, Evgeny Rossomacha, Sayaka Nakamura, Pratibha Potla, Sarah Gabrial, John Matelski, Anusha Ratneswaran, Kim Perry, Boris Hinz, Rajiv Gandhi, Igor Jurisica, Mohit Kapoor
doi : 10.1002/art.42285
Synovial fibrosis contributes to osteoarthritis (OA) pathology, but the underlying mechanisms remain unknown. We have observed increased microRNA-27b-3p (miR-27b-3p) levels in synovial fluid of patients with late-stage radiographic knee OA. Here, we investigated the contribution of miR-27b-3p to synovial fibrosis in patients with severe knee OA and in a mouse model of knee OA.
Xenofon Baraliakos, Atul Deodhar, Maxime Dougados, Lianne S. Gensler, Anna Molto, Sofia Ramiro, Alan J. Kivitz, Denis Poddubnyy, Marga Oortgiesen, Thomas Vaux, Carmen Fleurinck, Julie Shepherd-Smith, Christine de la Loge, Natasha de Peyrecave, Désirée van der Heijde
doi : 10.1002/art.42282
To assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active ankylosing spondylitis (AS).
Laura C. Coates, Iain B. McInnes, Joseph F. Merola, Richard B. Warren, Arthur Kavanaugh, Alice B. Gottlieb, Laure Gossec, Deepak Assudani, Rajan Bajracharya, Jason Coarse, Barbara Ink, Christopher T. Ritchlin
doi : 10.1002/art.42280
To assess the long-term safety, tolerability, and efficacy of bimekizumab in active psoriatic arthritis (PsA).
Luz P. Blanco, Eduardo Patino-Martinez, Shuichiro Nakabo, Mingzeng Zhang, Hege L. Pedersen, Xinghao Wang, Carmelo Carmona-Rivera, Dillon Claybaugh, Zu-Xi Yu, Equar Desta, Mariana J. Kaplan
doi : 10.1002/art.42284
Itaconic acid, a Krebs cycle–derived immunometabolite, is synthesized by myeloid cells in response to danger signals to control inflammasome activation, type I interferon (IFN) responses, and oxidative stress. As these pathways are dysregulated in systemic lupus erythematosus (SLE), we investigated the role of an itaconic acid derivative in the treatment of established murine lupus.
Xu-Fan Wang, Wen-Jing Xu, Fei-Fei Wang, Rui Leng, Xiao-Ke Yang, Hua-Zhi Ling, Yin-Guang Fan, Jin-Hui Tao, Zong-Wen Shuai, Li Zhang, Dong-Qing Ye, Rui-Xue Leng
doi : 10.1002/art.42304
Previous observational studies demonstrated that a subset of patients with systemic lupus erythematosus (SLE) have markedly short telomere length in leukocytes. This study was undertaken to test whether leukocyte telomere length is causally associated with risk of SLE.
Diana Trutschel, Pierre Bost, Xavier Mariette, Vincent Bondet, Alba Llibre, Celine Posseme, Bruno Charbit, Christian W. Thorball, Roland Jonsson, Christopher J. Lessard, Renaud Felten, Wan Fai Ng, Lucienne Chatenoud, Hélène Dumortier, Jean Sibilia, Jacques Fellay, Karl A. Brokstad, Silke Appel, Jessica R. Tarn, Lluis Quintana-Murci, Michael Mingueneau, Nicolas Meyer, Darragh Duffy, Benno Schwikowski, Jacques Eric Gottenberg, on behalf of The Milieu Intérieur Consortium, ASSESS study investigators, and NECESSITY Consortium
doi : 10.1002/art.42265
Primary Sjögren's syndrome (SS) is the second most frequent systemic autoimmune disease, affecting 0.1% of the general population. To characterize the molecular and clinical variabilities among patients with primary SS, we integrated transcriptomic, proteomic, cellular, and genetic data with clinical phenotypes in a cohort of 351 patients with primary SS.
Anna Papazoglou, Mengqi Huang, Melissa Bulik, Annika Lafyatis, Tracy Tabib, Christina Morse, John Sembrat, Mauricio Rojas, Eleanor Valenzi, Robert Lafyatis
doi : 10.1002/art.42286
Systemic sclerosis–associated interstitial lung disease (SSc-ILD) is the leading cause of death in patients with SSc with unclear pathogenesis and limited treatment options. Evidence strongly supports an important role for profibrotic secreted phosphoprotein 1 (SPP1)–expressing macrophages in SSc-ILD. This study was undertaken to define the transcriptome and chromatin structural changes of SPP1 SSc-ILD macrophages in order to better understand their role in promoting fibrosis and to identify transcription factors associated with open chromatin driving their altered phenotype.
Fei Yan, Xiaomei Xue, Jie Lu, Nicola Dalbeth, Han Qi, Qing Yu, Can Wang, Mingshu Sun, Lingling Cui, Zhen Liu, Yuwei He, Xuan Yuan, Ying Chen, Xiaoyu Cheng, Lidan Ma, Hailong Li, Aichang Ji, Shuhui Hu, Zijing Ran, Robert Terkeltaub, Changgui Li
doi : 10.1002/art.42266
The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate-lowering therapy (ULT) recommendation is first-line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia. This comparative effectiveness clinical trial was undertaken to compare first-line nontitrated low-dose benzbromarone (LDBen) uricosuric therapy to XOI ULT with low-dose febuxostat (LDFeb) in gout patients with renal uric acid underexcretion.
Jessica L. Turnier, Christine M. Yee, Jacqueline A. Madison, Syed M. Rizvi, Celine C. Berthier, Fei Wen, J. Michelle Kahlenberg
doi : 10.1002/art.42283
Cutaneous inflammation can signal disease in juvenile dermatomyositis (DM) and childhood-onset systemic lupus erythematosus (cSLE), but we do not fully understand cellular mechanisms of cutaneous inflammation. In this study, we used imaging mass cytometry to characterize cutaneous inflammatory cell populations and cell–cell interactions in juvenile DM as compared to cSLE.
Gregg E. Dinse, Christine G. Parks, Clarice R. Weinberg, Caroll A. Co, Jesse Wilkerson, Darryl C. Zeldin, Edward K. L. Chan, Frederick W. Miller
doi : 10.1002/art.42330
Growing evidence suggests increasing frequencies of autoimmunity and autoimmune diseases, but findings are limited by the lack of systematic data and evolving approaches and definitions. This study was undertaken to investigate whether the prevalence of antinuclear antibodies (ANA), the most common biomarker of autoimmunity, changed over a recent 25-year span in the US.
Man-Man Niu, Qi Jiang, Yan-Fang Zhang, Dao-Ting Li, Qian Yang, Peng Hu
doi : 10.1002/art.42303
Joydeep Samanta, Alekhya Amudalapalli, Ashlesha Shukla, BV Harish, Sudhish Gadde, Rasmi R. Sahoo, Pradeepta S. Patro
doi : 10.1002/art.42302
Eric Toussirot, Caroline Laheurte, Philippe Saas
doi : 10.1002/art.42278
Nicolas Rosine, Lars Rogge, Dennis McGonagle, Corinne Miceli-Richard
doi : 10.1002/art.42277
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟